This first documented case demonstrates the therapeutic efficacy of crizotinib in ALK-IR rearranged NSCLC, emphasizing the importance of comprehensive molecular profiling in guiding precision oncology.

The results of the ADAURA trial led to the approval of osimertinib for adjuvant treatment of completely resected, EGFR-mutated NSCLC, while the ALINA trial provided the basis for the approval of alectinib in the adjuvant treatment of ALK-positive, completely resected NSCLC. This article discusses the current evidence regarding the perioperative use of targeted therapies, the recommendations for molecular testing in non-small cell lung cancer, and the resulting therapeutic implications, as well as ongoing research efforts in this evolving field.

P=N/A, N=24, Recruiting, Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo

The patient was treated with the oral targeted drug crizotinib and died of multiple organ failure 18 months after surgery...UIMT and EIMS that exhibit aggressive behavior typically possess a greater number of genetic alterations. The abnormal expression of p53 or p16 protein, when combined with clinicopathological parameters, can serve as indicators for predicting the adverse biological behavior of tumors.

Notably, C479 exhibited in vitro inhibitory activity comparable to Brigatinib. All the results indicate that the candidate compounds not only possess inhibitory activity similar to that of Brigatinib, but may also help diversify the existing repertoire of ALK-targeted agents and provide additional options for NSCLC research.

This case adds to the limited body of evidence and underscores the importance of recognizing neuroendocrine differentiation in ALK-positive lung cancer cases which show clinical progression. Further studies are needed to elucidate the molecular drivers of this transformation and to optimize treatment strategies for affected patients.

This case illustrates the successful personalization of neoadjuvant alectinib by employing an imaging response-adapted strategy. This strategy utilized dynamic imaging assessments to guide the scheduling of the surgical procedure, culminating in a deep pathological response and prolonged disease-free survival, thereby offering a refined perioperative paradigm for ALK-rearranged NSCLC.

Despite robust evidence supporting ALK-targeted therapies, this study highlights substantial disparities in access to diagnostics and treatment for ALK-rearranged NSCLC in Brazil, particularly among patients reliant on the public health care system. Findings underscore the need for policies to strengthen testing infrastructure, ensure equitable access to guideline-recommended therapies, and enhance provider education. Addressing these gaps is essential for equitable precision oncology and improved outcomes.

Knockdown of NTRK1, which encodes TrkA, reduced cell viability and sensitized ATC cells to paclitaxel. Entrectinib was well tolerated at the administered dose, with no significant changes in body weight and serum biochemical markers. Collectively, these findings identify TrkA as a potential therapeutic target in ATC and support further investigation of entrectinib-based combination strategies to improve ATC treatment outcomes.

Although rare, GI perforation, represents a clinically relevant adverse event associated with alectinib, particularly in patients with diverticulosis or other predisposing conditions. It is essential to optimize safety and long-term disease control by raising awareness of early warning symptoms, conducting a baseline GI evaluation in high-risk patients and carefully sequencing therapy after discontinuation.

This case demonstrates that iruplinalkib exhibits excellent efficacy and tolerability in elderly patients with ALK-positive NSCLC, even in those presenting with advanced disease and poor initial performance status. Age alone should not preclude consideration of targeted therapy when actionable driver mutations are identified.

Upon light irradiation, the caged compound undergoes efficient uncaging to release active Crizotinib, restoring its potent kinase inhibitory and antiproliferative activities. This work establishes BODIPY-caged Crizotinib as a promising photoactivatable agent for precision cancer therapy.